RxDoctor Payments Data

Allison Eaton, MD

Gynecology · Knoxville, TNNPI 1124222963

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 50 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 16.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $431 and has fallen 79.7% since, to $87 in 2025.

$1,098in general payments, 2019–2025

Across 50 payments — averaging $21.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Emmaus Medical, Inc.$180
  • AbbVie$153
  • Sumitomo Pharma America, Inc.$124
  • Exeltis, USA Inc.$74
  • Astellas Pharma US Inc$70
  • C. R. Bard, Inc. & Subsidiaries$58
  • plus $440 from 20 others

What the payments were for

  • Food & beverage$1,098100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,098 in reported general payments places this provider in the 65th percentile of 57 gynecology providers in Tennessee.

See all gynecology providers in Tennessee

Medicare billing

Part B allowed, 2024
$12,041
Medicare patients
107
Services billed
179

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PremarinEstrogens, Conjugated19$12,328
PremproEstrogen,con/M-Progest Acet12$2,731
Estradiol79$2,689
ProgesteroneProgesterone, Micronized40$2,179
YuvafemEstradiol15$2,035
Clobetasol Propionate41$1,159
CryselleNorgestrel-Ethinyl Estradiol15$402
Triamcinolone Acetonide37$317
Alendronate Sodium11$40

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerPremarin, Prempro$34$15,06031 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 57 gynecology providers in Tennessee.

Other gynecology in Knoxville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →